Entity Central Index Key
Amount of accumulated amortization of intangible assets, excluding goodwill.
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Annual Report
Document Annual Report
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Document Transition Report
Document Transition Report
Entity File Number
Entity File Number
Entity Registrant Name
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Title of 12(b) Security
Security12b Title
ICFR Auditor Attestation Flag
Icfr Auditor Attestation Flag
Trading Symbol
Trading Symbol
Security Exchange Name
Security Exchange Name
Entity Well Known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Voluntary Filers
Entity Voluntary Filers
Entity Current Reporting Status
Entity Current Reporting Status
Entity Interactive Data Current
Entity Interactive Data Current
Entity Filer Category
Entity Filer Category
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Ex Transition Period
Entity Shell Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Entity Public Float
Entity Public Float
Put option liability current.
Statement Of Financial Position [Abstract]
Assets
Assets [Abstract]
Current assets
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Accounts receivable, net
Accounts Receivable Net Current
Other current assets
Other Assets Current
Total current assets
Assets Current
Non‑current assets
Assets Noncurrent [Abstract]
Property and equipment, net
Property Plant And Equipment Net
Intangible assets, net
Intangible Assets Net Excluding Goodwill
Other long-term assets
Other Assets Noncurrent
Goodwill
Goodwill
Total non‑current assets
Assets Noncurrent
Total assets
Assets
Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)
Liabilities And Stockholders Equity [Abstract]
Current liabilities
Liabilities Current [Abstract]
Accounts payable
Accounts Payable Current
Accrued liabilities
Accrued Liabilities Current
Deferred revenue
Contract With Customer Liability Current
Current portion of notes payable
Notes Payable To Bank Current
Put option liability
Put Option Liability Current
Total current liabilities
Liabilities Current
Non‑current liabilities
Liabilities Noncurrent [Abstract]
Warrant liability
Warrants And Rights Outstanding
Long‑term notes payable
Long Term Notes Payable
Contingent consideration
Business Combination Contingent Consideration Liability Noncurrent
Other long-term liabilities
Other Liabilities Noncurrent
Total non‑current liabilities
Liabilities Noncurrent
Total liabilities
Liabilities
Commitments and contingencies
Commitments And Contingencies
Convertible preferred stock
Temporary Equity [Abstract]
Convertible preferred stock, $0.001 par value, 0 (2020) and 174,237,067 (2019) authorized; 0 (2020) and 118,766,273 (2019) issued and outstanding; liquidation preference of $202,582 (2019)
Temporary Equity Carrying Amount Attributable To Parent
Stockholders' equity (deficit)
Stockholders Equity [Abstract]
Preferred stock, $0.001 par value, 5,000,000 (2020) and 0 (2019) authorized; 0 (2020 and 2019) issued and outstanding
Preferred Stock Value
Common stock, $0.001 par value, 200,000,000 (2020) and 190,000,000 (2019) authorized; 26,561,504 (2020) and 254,918 (2019) issued and outstanding
Common Stock Value
Additional paid‑in capital
Additional Paid In Capital
Accumulated deficit
Retained Earnings Accumulated Deficit
Total stockholders' equity (deficit)
Stockholders Equity
Total liabilities, convertible preferred stock and stockholders' equity (deficit)
Liabilities And Stockholders Equity
Convertible preferred stock, par value
Temporary Equity Par Or Stated Value Per Share
Convertible preferred stock, authorized
Temporary Equity Shares Authorized
Convertible preferred stock, issued
Temporary Equity Shares Issued
Convertible preferred stock, outstanding
Temporary Equity Shares Outstanding
Convertible preferred stock, liquidation preference
Temporary Equity Liquidation Preference
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred stock, authorized
Preferred Stock Shares Authorized
Preferred stock, issued
Preferred Stock Shares Issued
Preferred stock, outstanding
Preferred Stock Shares Outstanding
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, authorized
Common Stock Shares Authorized
Common stock, issued
Common Stock Shares Issued
Common stock, outstanding
Common Stock Shares Outstanding
Direct costs and expenses.
Change in fair value of contingent consideration excluding accretion expense.
Change in fair value of put option liability.
Income Statement [Abstract]
Revenues
Revenues
Operating expenses:
Operating Expenses [Abstract]
Direct costs and expenses
Direct Costs And Expenses
Research and development
Research And Development Expense
Sales, marketing, general and administrative
Selling General And Administrative Expense
Change in fair value of contingent consideration
Change In Fair Value Of Contingent Consideration Excluding Accretion Expense
Total operating expenses
Operating Expenses
Loss from operations
Operating Income Loss
Other income (expense):
Other Income And Expenses [Abstract]
Interest income
Interest Income Other
Interest expense
Interest Expense
Change in fair value of warrant liability
Fair Value Adjustment Of Warrants
Change in fair value of put option liability
Change In Fair Value Of Put Option Liability
Other income, net
Other Nonoperating Income
Total other expense
Other Nonoperating Income Expense
Net loss
Net Income Loss
Net loss per share, basic and diluted
Earnings Per Share Basic And Diluted
Weighted-average shares outstanding, basic and diluted
Weighted Average Number Of Share Outstanding Basic And Diluted
Temporary equity stock issued during period shares new issues.
Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.
Statement Of Stockholders Equity [Abstract]
Statement [Table]
Statement [Table]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common Stock
Common Stock [Member]
Additional Paid-in Capital
Additional Paid In Capital [Member]
Accumulated Deficit
Retained Earnings [Member]
Class of Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Convertible Preferred Stock
Convertible Preferred Stock [Member]
Statement [Line Items]
Statement [Line Items]
Balance
Temporary Equity Balance, Shares
Common stock issued upon exercise of stock options
Stock Issued During Period Value Stock Options Exercised
Common stock issued upon exercise of stock options, shares
Stock Issued During Period Shares Stock Options Exercised
Issuance of Series H Preferred Stock
Temporary Equity Stock Issued During Period Value New Issues
Issuance of Series H Preferred Stock, shares
Temporary Equity Stock Issued During Period Shares New Issues
Stock‑based compensation expense
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Issuance of common stock in initial public offering, net of discounts and commission of $5,040 and direct offering costs of $3,203
Stock Issued During Period Value New Issues
Issuance of common stock in initial public offering, net of discounts and commission and direct offering costs, shares
Stock Issued During Period Shares New Issues
Conversion of preferred stock into common stock upon initial public offering
Stock Issued During Period Value Conversion Of Convertible Securities
Conversion of preferred stock into common stock, shares
Stock Issued During Period Shares Conversion Of Convertible Securities
Conversion of convertible debt into common stock upon initial public offering
Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
Conversion of convertible debt into common stock, shares
Stock Issued During Period Shares Conversion Of Convertible Securities Common Stock
Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering
Adjustments To Additional Paid In Capital Warrant Issued
Net loss and comprehensive loss
Balance
Temporary Equity Balance, Shares
Sale of stock, temporary equity, price per share.
Temporary equity issuance costs.
Series H Convertible Preferred Stock
Series H Preferred Stock [Member]
Sale of stock, temporary equity, price per share
Sale Of Stock Temporary Equity Price Per Share
Issuance costs
Temporary Equity Issuance Costs
Discounts and commission
Capital Units Deductions From Total Cost To Investors
Direct offering costs
Capital Units Total Cost To Investors
Accrued interest on notes payable and convertible notes payable.
Payments for proceeds from patent costs and intangible asset acquisition, net.
Payments to acquire Oncimmune.
Statement Of Cash Flows [Abstract]
Cash flows from operating activities
Net Cash Provided By Used In Operating Activities [Abstract]
Net loss
Profit Loss
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Depreciation and amortization
Depreciation And Amortization
Amortization of convertible notes debt discount
Amortization Of Debt Discount Premium
Stock‑based compensation expense
Share Based Compensation
Change in fair value of warrant liability
Change in contingent consideration
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
Change in fair value of put option
Accrued interest on notes payable and convertible notes payable
Accrued Interest On Notes Payable And Convertible Notes Payable
Amortization of debt issuance costs
Amortization Of Financing Costs
Provision for doubtful accounts
Provision For Doubtful Accounts
Loss on disposals of assets
Gain Loss On Disposition Of Assets1
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in acquisitions:
Increase Decrease In Operating Capital [Abstract]
Accounts receivable
Increase Decrease In Accounts Receivable
Other current assets
Increase Decrease In Other Current Assets
Other long-term assets and liabilities
Increase Decrease In Other Noncurrent Assets And Liabilities Net
Accounts payable and other accrued liabilities
Increase Decrease In Accounts Payable And Accrued Liabilities
Deferred revenue
Increase Decrease In Contract With Customer Liability
Net cash and cash equivalents and restricted cash used in operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities
Net Cash Provided By Used In Investing Activities [Abstract]
Purchase of property and equipment
Payments To Acquire Property Plant And Equipment
Patent costs and intangible asset acquisition, net
Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
Payments to acquire Oncimmune assets
Payments To Acquire Oncimmune
Net cash and cash equivalents and restricted cash used in investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities
Net Cash Provided By Used In Financing Activities [Abstract]
Proceeds from initial public offering
Proceeds From Issuance Initial Public Offering
Proceeds from exercise of common stock options
Proceeds From Stock Options Exercised
Proceeds from issuance of series H preferred stock
Proceeds From Issuance Of Convertible Preferred Stock
Proceeds from issuances of convertible notes payable
Proceeds From Convertible Debt
Proceeds from paycheck protection program note payable
Proceeds From Notes Payable
Equity financing costs
Payments Of Stock Issuance Costs
Other
Proceeds From Payments For Other Financing Activities
Net cash and cash equivalents and restricted cash provided by financing activities
Net Cash Provided By Used In Financing Activities
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash, cash equivalents, and restricted cash ‑ beginning of period
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash, cash equivalents, and restricted cash ‑ end of period
Conversion of preferred stock into common stock.
Reclassification of put option liability to additional paid in capital.
Value of put option recorded at issuance of convertible notes payable.
Reclassification of warrant liability to additional paid-in-capital.
Supplemental cash flow information
Supplemental Cash Flow Information [Abstract]
Conversion of preferred stock into common stock
Conversion Of Preferred Stock Into Common Stock
Conversion of convertible notes and accrued interest into common stock
Conversion Of Stock Amount Converted1
Reclassification of put option liability to additional paid-in capital
Reclassification Of Put Option Liability To Additional Paid In Capital
Value of put option recorded at issuance of convertible debt payable
Value Of Put Option Recorded At Issuance Of Convertible Notes Payable
Cash paid for interest
Interest Paid Net
Reclassification of warrant liability to additional paid-in capital
Reclassification Of Warrant Liability To Additional Paid In Capital
Accrued business combination payments
Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
Cash paid for income taxes
Income Taxes Paid Net
Documents Incorporated by Reference
Documents Incorporated By Reference [Text Block]
Organization and description of business.
Organization And Description Of Business [Abstract]
Organization and Description of Business
Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]
Recent Accounting Pronouncements
New Accounting Pronouncements And Changes In Accounting Principles [Text Block]
Business Combinations [Abstract]
Business Combinations
Business Combination Disclosure [Text Block]
Fair Value Disclosures [Abstract]
Fair Value
Fair Value Disclosures [Text Block]
Property Plant And Equipment [Abstract]
Property and Equipment
Property Plant And Equipment Disclosure [Text Block]
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets
Goodwill And Intangible Assets Disclosure [Text Block]
Payables And Accruals [Abstract]
Accrued Liabilities
Accounts Payable And Accrued Liabilities Disclosure [Text Block]
Debt Disclosure [Abstract]
Debt
Debt Disclosure [Text Block]
Class Of Stock Disclosures [Abstract]
Convertible Preferred Stock
Preferred Stock [Text Block]
Warrants for convertible preferred stock.
Warrants And Rights Note Disclosure [Abstract]
Warrants to Purchase Convertible Preferred Stock
Warrants For Convertible Preferred Stock [Text Block]
Stockholders Equity Note [Abstract]
Equity
Stockholders Equity Note Disclosure [Text Block]
Revenue From Contract With Customer [Abstract]
Revenue
Revenue From Contract With Customer [Text Block]
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation
Disclosure Of Compensation Related Costs Share Based Payments [Text Block]
Earnings Per Share [Abstract]
Earnings per Share
Earnings Per Share [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies
Commitments And Contingencies Disclosure [Text Block]
Compensation And Retirement Disclosure [Abstract]
Defined Contribution 401(k) Plan
Defined Contribution Plan [Text Block]
Disclosure of accounting policy for reverse stock split.
Reverse Stock Split
Reverse Stock Split Policy [Text Block]
Disclosure of accounting policy for approval of amended and restated certificate of incorporation.
Approval of Amended and Restated Certificate of Incorporation
Approval Of Amended And Restated Certificate Of Incorporation Policy [Text Block]
Disclosure of accounting policy for initial public offering.
Initial Public Offering ("IPO")
Initial Public Offering I P O Policy [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Segment Reporting
Segment Reporting Policy Policy [Text Block]
Use of Estimates
Use Of Estimates
Revenue Recognition
Revenue Recognition Policy [Text Block]
Deferred Revenue
Revenue From Contract With Customer Policy [Text Block]
Direct costs and expenses policy.
Direct Costs and Expenses
Direct Costs And Expenses Policy [Text Block]
Research and Development Expenses
Research And Development Expense Policy
Sales, Marketing, General and Administrative Expenses
Selling General And Administrative Expenses Policy [Text Block]
Concentrations of Credit Risk and Other Uncertainties
Concentration Risk Credit Risk
Cash and Cash Equivalents
Cash And Cash Equivalents Policy [Text Block]
Restricted Cash
Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy
Accounts Receivable and Allowance for Doubtful Accounts
Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy
Inventory
Inventory Supplies Policy
Property and Equipment
Property Plant And Equipment Policy [Text Block]
Intangible Assets
Goodwill And Intangible Assets Intangible Assets Policy
Goodwill
Goodwill And Intangible Assets Goodwill Policy
Fair Value of Financial Instruments
Fair Value Measurement Policy Policy [Text Block]
Disclosure of accounting policy for contingent consideration.
Contingent Consideration
Contingent Consideration Policy [Text Block]
Disclosure of accounting policy for warrant liability.
Warrant Liability
Warrant Liability Policy [Text Block]
Disclosure of accounting policy for put-option liability
Put Option Liability
Put Option Liability Policy [Text Block]
Share-Based Compensation
Share Based Compensation Option And Incentive Plans Policy
Net Loss per Common Share
Earnings Per Share Policy [Text Block]
Recently Issued Accounting Standards Not Yet Adopted
New Accounting Pronouncements Policy Policy [Text Block]
Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers
Schedules Of Concentration Of Risk By Risk Factor [Text Block]
Summary of Aggregate Consideration Paid by Company and Allocation of Purchase Price to Assets Acquired and Liabilities Assumed
Business Combination Segment Allocation Table [Text Block]
Summary of Fair Value of Outstanding Borrowings
Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments Table [Text Block]
Schedule of Reported Fair values of Liabilities
Fair Value Liabilities Measured On Recurring Basis [Text Block]
Schedule of Changes in Financial Liabilities
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]
Schedule of Property and Equipment
Property Plant And Equipment [Text Block]
Schedule of depreciation and amortization expense related to property and equipment.
Schedule of Depreciation Expense Related to Property and Equipment
Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]
Schedule of Changes in Goodwill
Schedule Of Goodwill [Text Block]
Schedule of Intangible Assets
Schedule Of Intangible Assets And Goodwill Table [Text Block]
Schedule of Amortization Expense Related to Definite-Lived Intangible Assets
Finite Lived Intangible Assets Amortization Expense Table [Text Block]
Schedule of Future Estimated Amortization Expense of Intangible Assets
Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]
Schedule of Accrued Liabilities
Schedule Of Accrued Liabilities Table [Text Block]
Summary of Long-term Notes Payable
Schedule Of Debt Instruments [Text Block]
Scheduled Principal Repayments (Maturities) of Long-term Obligations
Schedule Of Maturities Of Long Term Debt Table [Text Block]
Summary of Activity for Convertible Preferred Stock Warrants
Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]
Summary of Revenue
Disaggregation Of Revenue Table [Text Block]
Summary of Pre-tax Share-based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Summary of Stock Option Activity
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Summary of Weighted Average Assumptions
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]
Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]
Schedule of Effective Income Tax Rate Reconciliation
Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]
Schedule of Deferred Tax Assets and Liabilities
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Reconciliation of Unrecognized Tax Benefits
Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]
Summary of Future Minimum Lease Payments for Operating Lease Obligations
Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]
Number of cancer test.
Organization and description of business.
Organization and description of business.
Organization And Description Of Business [Table]
Organization And Description Of Business [Table]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Initial Public Offering
I P O [Member]
Organization And Description Of Business [Line Items]
Organization And Description Of Business [Line Items]
Number of blood based lung cancer test
Number Of Cancer Test
Number of commercial blood based test.
Number of commercial blood-based test
Number Of Commercial Blood Based Test
Number of SARS-CoV-2 test.
Number of SARS-CoV-2 test
Number Of S A R S Co V2 Test
Reverse stock split, description
Stockholders Equity Reverse Stock Split
Reverse stock split ratio
Stockholders Equity Note Stock Split Conversion Ratio1
Common stock, shares authorized
Common stock, par value
Preferred stock, shares authorized
Preferred stock, par value
Convertible preferred stock and convertible notes payable converted to common stock.
Shares of common stock issued and sold
Common stock price per share
Shares Issued Price Per Share
Convertible preferred stock and convertible notes payable converted into shares of common stock
Convertible Preferred Stock And Convertible Notes Payable Converted To Common Stock
Warrants to purchase shares of common stock
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Increase decrease in accumulated deficit.
Summary Of Significant Accounting Policies [Line Items].
Summary of significant accounting policies.
Summary Of Significant Accounting Policies [Table]
Summary Of Significant Accounting Policies [Table]
Revision of Prior Period
Restatement [Axis]
Revision of Prior Period
Restatement [Domain]
Revision of Prior Period, Error Correction, Adjustment
Revision Of Prior Period Error Correction Adjustment [Member]
Product and Service
Product Or Service [Axis]
Product and Service
Products And Services [Domain]
Testing services.
Testing Services
Testing Services [Member]
Concentration Risk Benchmark
Concentration Risk By Benchmark [Axis]
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Revenue
Sales Revenue Net [Member]
Concentration Risk Type
Concentration Risk By Type [Axis]
Concentration Risk Type
Concentration Risk Type [Domain]
Customer Concentration Risk
Customer Concentration Risk [Member]
Customer
Major Customers [Axis]
Customer
Name Of Major Customer [Domain]
Covance Central Laboratory Services.
Covance Central Laboratory Services
Covance Central Laboratory Services [Member]
Medicare.
Medicare
Medicare [Member]
Balance Sheet Location
Balance Sheet Location [Axis]
Balance Sheet Location
Balance Sheet Location [Domain]
Other Current Assets
Other Current Assets [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
Finite-Lived Intangible Assets by Major Class
Finite Lived Intangible Assets By Major Class [Axis]
Finite-Lived Intangible Assets, Major Class Name
Finite Lived Intangible Assets Major Class Name [Domain]
Product life and patent life.
Product Life and Patent Life
Product Life And Patent Life [Member]
Summary Of Significant Accounting Policies [Line Items]
Summary Of Significant Accounting Policies [Line Items]
Increase in goodwill
Goodwill Period Increase Decrease
Reduction in accumulated deficit
Increase Decrease In Accumulated Deficit
Error corrections and prior period adjustments, description
Error Corrections And Prior Period Adjustments Description
Number of operating segments
Number Of Operating Segments
Segment Reporting [Abstract]
Concentration Risk [Table]
Concentration Risk [Table]
The Big Ten Conference.
The Big Ten Conference
The Big Ten Conference [Member]
Centura Healthcare.
Centura Healthcare
Centura Healthcare [Member]
Accounts Receivable
Accounts Receivable [Member]
Janssen Research and Development, LLC.
Janssen Research and Development, LLC
Janssen Research And Development L L C [Member]
Pfizer, Inc.
Pfizer, Inc
Pfizer Inc [Member]
Concentration Risk [Line Items]
Concentration Risk [Line Items]
Concentration risk, percentage
Concentration Risk Percentage1
Restricted cash
Restricted Cash
Allowance for doubtful accounts
Allowance For Doubtful Accounts Receivable
Inventory
Other Inventory Supplies
Property, plant and equipment, useful Lives
Property Plant And Equipment Useful Life
Impairment of long-lived assets
Impairment Of Long Lived Assets Held For Use
Finite-lived intangible asset, useful life
Finite Lived Intangible Asset Useful Life
Impairment of intangible assets
Impairment Of Intangible Assets Excluding Goodwill
Goodwill impairments loss
Goodwill Impairment Loss
Schedule Of Business Acquisitions By Acquisition [Table]
Schedule Of Business Acquisitions By Acquisition [Table]
License Rights
License [Member]
Business Acquisition
Business Acquisition [Axis]
Business Acquisition, Acquiree
Business Acquisition Acquiree [Domain]
Oncimmune Limited.
Oncimmune Limited
Oncimmune Limited [Member]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
United States
UNITED STATES
Integrated Diagnostics, Inc.
Integrated Diagnostics, Inc
Integrated Diagnostics Inc [Member]
Investment Type
Investment Type [Axis]
Investments
Investment Type Categorization [Member]
Repurchase.
Repurchase
Repurchase [Member]
Business Acquisition [Line Items]
Business Acquisition [Line Items]
Total consideration amount
Business Combination Consideration Transferred1
Business acquisition description
Business Acquisition Description Of Acquired Entity
Payments to acquire license rights
Other Payments To Acquire Businesses
Cash
Payments To Acquire Businesses Gross
Business combination recognized identifiable assets acquired and liabilities assumed purchase option.
Total fair value of consideration transferred
Deposit
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Marketable Securities
Inventory
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory
Property and equipment
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
Purchase option
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Purchase Option
Accrued liabilities
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
Total
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
Contingent consideration estimated fair value
Contingent Consideration Classified As Equity Fair Value Disclosure
Business acquisition contingent consideration gross margin target period.
Business acquisition contingent consideration number of installments.
Business combination contingent consideration arrangements common shares redemption amount.
Business combination contingent consideration shares.
Business acquisition contingent consideration gross margin target
Cash Acquired From Acquisition
Business acquisition contingent consideration gross margin target period
Business Acquisition Contingent Consideration Gross Margin Target Period
Contingent consideration shares
Business Combination Contingent Consideration Shares
Contingent consideration number of installments
Business Acquisition Contingent Consideration Number Of Installments
Contingent consideration arrangements, common shares, redemption amount
Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount
Contingent consideration cash payment
Payments To Acquire Businesses Net Of Cash Acquired
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
Disclosure of information about liabilities measured at fair value on recurring basis.
Fair Value Liabilities Measured On Recurring Basis [Table]
Fair Value Liabilities Measured On Recurring Basis [Table]
Measurement Basis
Fair Value By Measurement Basis [Axis]
Fair Value Disclosure Item Amounts [Default]
Portion At Fair Value Fair Value Disclosure [Member]
Fair Value Measurement
Fair Value Disclosure Item Amounts [Domain]
Carrying Value
Carrying Reported Amount Fair Value Disclosure [Member]
Fair Value
Estimate Of Fair Value Fair Value Disclosure [Member]
Measurement Frequency
Fair Value By Measurement Frequency [Axis]
Measurement Frequency
Fair Value Measurement Frequency [Domain]
Fair Value, Recurring
Fair Value Measurements Recurring [Member]
Fair Value Hierarchy and NAV
Fair Value By Fair Value Hierarchy Level [Axis]
Fair Value Hierarchy and NAV
Fair Value Measurements Fair Value Hierarchy [Domain]
Level 2
Fair Value Inputs Level2 [Member]
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Fair Value Liabilities Measured On Recurring Basis [Line Items]
Borrowings
Long Term Debt Fair Value
Liability Class
Fair Value By Liability Class [Axis]
Fair Value by Liability Class
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]
Contingent consideration.
Contingent Consideration
Contingent Consideration [Member]
Put option liability.
Put Option Liability
Put Option Liability [Member]
Warrant liability.
Warrant Liability
Warrant Liability [Member]
Contingent value rights.
Contingent Value Rights
Contingent Value Rights [Member]
Level 3
Fair Value Inputs Level3 [Member]
Total liabilities
Liabilities Fair Value Disclosure
Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balances
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
Additions
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
Changes in fair value
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
Reclassified to additional paid-in capital
Fair Value Measurement With Unobservable Inputs Reconciliation Reclassified To Additional Paid In Capital
Ending balances
Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Minimum
Maximum
Long-term Debt, Type
Longterm Debt Type [Axis]
Long-term Debt, Type
Longterm Debt Type [Domain]
Notes payable 2018 notes.
2018 Notes
Notes Payable2018 Notes [Member]
Series G Preferred Stock
Series G Preferred Stock [Member]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
Aveo oncology.
AVEO Oncology
A V E O Oncology [Member]
Series F Preferred Stock
Series F Preferred Stock [Member]
Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range
Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range
Warrant issued to purchase shares
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
Warrant, exercise price
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Warrants, expires period
Warrants And Rights Outstanding Maturity Date
Estimated air value of warrants issued
Warrants Not Settleable In Cash Fair Value Disclosure
Warrant issued to purchase shares
Increase in value of the warrant liability
Contingent value rights shares.
Contingent value rights.
Net proceeds percentage of cash payment to the cvr holders.
Contingent value rights percentage.
Percentage of development and regulatory costs exercised using opt-out right.
Contingent value rights shares
Contingent Value Rights Shares
Contingent value rights
Contingent Value Rights
Contingent value rights percentage
Contingent Value Rights Percentage
Net proceeds percentage of cash payment to the CVR holders
Net Proceeds Percentage Of Cash Payment To C V R Holders
Percentage of development and regulatory costs exercised using opt-out right
Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Lab Equipment
Equipment [Member]
Leasehold Improvements
Leasehold Improvements [Member]
Computer Equipment
Computer Equipment [Member]
Furniture and Fixtures
Furniture And Fixtures [Member]
Software
Software And Software Development Costs [Member]
Construction in Process
Construction In Progress [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Property and equipment, gross
Property Plant And Equipment Gross
Less accumulated depreciation
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Total property and equipment, net
Asset Class
Fair Value By Asset Class [Axis]
Asset Class
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]
Property and Equipment
Property Plant And Equipment [Member]
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Direct costs and expenses.
Direct Costs and Expenses
Direct Costs And Expenses [Member]
Sales, Marketing, General and Administrative
Selling General And Administrative Expenses [Member]
Depreciation expense
Depreciation
Beginning balance
Attributable to acquisition of Oncimmune, Ltd.
Goodwill Acquired During Period
Ending balance
Finite Lived Intangible Assets Net [Abstract]
Schedule Of Finite Lived Intangible Assets [Table]
Schedule Of Finite Lived Intangible Assets [Table]
Patents
Patents [Member]
Purchased technology.
Purchased Technology
Purchased Technology [Member]
Purchase option.
Purchase Option
Purchase Option [Member]
Indefinite-lived Intangible Assets
Indefinite Lived Intangible Assets By Major Class [Axis]
Indefinite-lived Intangible Assets, Major Class Name
Indefinite Lived Intangible Assets Major Class Name [Domain]
Trademarks
Trademarks [Member]
Finite Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets [Line Items]
Intangible assets subject to amortization, Cost
Finite Lived Intangible Assets Gross
Intangible assets subject to amortization, Accumulated Amortization
Finite Lived Intangible Assets Accumulated Amortization
Intangible assets subject to amortization, Net Carrying Value
Finite Lived Intangible Assets Net
Indefinite lived intangible assets excluding goodwill gross.
Intangible assets not subject to amortization, Cost
Indefinite Lived Intangible Assets Excluding Goodwill Gross
Intangible assets not subject to amortization, Net Carrying Value
Indefinite Lived Intangible Assets Excluding Goodwill
Intangible assets, Cost
Intangible Assets Gross Excluding Goodwill
Intangible assets, Accumulated Amortization
Intangible Assets Accumulated Amortization Excluding Goodwill
Intangible assets, Net Carrying Value
Amortization expense related to definite-lived intangible assets
Amortization Of Intangible Assets
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2021
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
2022
Finite Lived Intangible Assets Amortization Expense Year Two
2023
Finite Lived Intangible Assets Amortization Expense Year Three
2024
Finite Lived Intangible Assets Amortization Expense Year Four
2025
Finite Lived Intangible Assets Amortization Expense Year Five
Thereafter
Finite Lived Intangible Assets Amortization Expense After Year Five
Impairments of intangible assets
Goodwill And Intangible Asset Impairment
Accrued clinical trial expense current.
Compensation related accruals
Employee Related Liabilities Current
Accrued clinical trial expense
Accrued Clinical Trial Expense Current
Other expenses
Other Accrued Liabilities Current
Warrant liability, current
Product Warranty Accrual Classified Current
Total accrued liabilities
Debt Instruments [Abstract]
Debt Instrument [Table]
Debt Instrument [Table]
PPP loan.
PPP Loan
P P P Loan [Member]
Debt Instrument
Debt Instrument [Axis]
Debt Instrument, Name
Debt Instrument Name [Domain]
CARES act.
CARES Act
C A R E S Act [Member]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Notes/Loan payable
Debt Instrument Carrying Amount
Convertible notes payable
Convertible Notes Payable Current
Unamortized debt discount and debt issuance costs
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
Notes payable, total
Notes Payable
Less: current maturities
Notes Payable Current
Interest-bearing Deposits
Interest Bearing Deposits [Member]
Short-term Debt, Type
Short Term Debt Type [Axis]
Short-term Debt, Type
Short Term Debt Type [Domain]
March two thousand and twenty convertible notes.
March 2020 Notes
March Two Thousand And Twenty Convertible Notes [Member]
Debt Instrument, Redemption, Period
Debt Instrument Redemption Period [Axis]
Debt Instrument, Redemption, Period
Debt Instrument Redemption Period [Domain]
First Tranche
Debt Instrument Redemption Period One [Member]
Second Tranche
Debt Instrument Redemption Period Two [Member]
December two thousand and nineteen convertible notes.
December 2019 Notes
December Two Thousand And Nineteen Convertible Notes [Member]
August two thousand and nineteen convertible notes.
August 2019 Notes
August Two Thousand And Nineteen Convertible Notes [Member]
Loan principle amount
Debt instrument, percentage of stated interest rate, paid in cash.
Debt instrument, percentage of stated interest rate added to principal value of notes payable.
Debt instrument interest added to principal value.
Facility fee amount
Debt Instrument Fee Amount
Warrant issued to purchase shares
Interest rate
Debt Instrument Interest Rate Stated Percentage
Percentage of interest rate, paid in cash
Debt Instrument Percentage Of Stated Interest Rate Paid In Cash
Percentage of interest rate added to principal value of notes payable
Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable
Interest added to principal value
Debt Instrument Interest Added To Principal Value
Frequency of periodic payment
Debt Instrument Frequency Of Periodic Payment
Debt instrument prepayment penalty percentage.
Debt instrument back-end facility fee percentage.
Debt instrument additional interest expense fee percentage.
Debt instrument, prepayment penalty
Debt Instrument Prepayment Penalty Percentage
Debt instrument, back-end facility fee
Debt Instrument Back End Facility Fee Percentage
Debt instrument, additional interest expense fee
Debt Instrument Additional Interest Expense Fee Percentage
Early amortization of loan payment schedule
Debt Instrument Convertible Remaining Discount Amortization Period1
Loan description
Debt Instrument Description
Payroll costs excludes compensation of an employee.
Percentage for non-payroll costs.
Upper limit of employee salary to reduce forgiveness.
Percentage of upper limit of employee salary to reduce forgiveness.
Payroll costs excludes compensation of an employee
Payroll Costs Excludes Compensation Of Employee
Percentage for non-payroll costs
Percentage For Non Payroll Costs
Upper limit of employee salary to reduce forgiveness
Upper Limit Of Employee Salary To Reduce Forgiveness
Percentage of upper limit of employee salary to reduce forgiveness
Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness
Percentage of conversion price per share of common stock.
Debt instrument maturity date extended.
Convertible notes payable
Notes Issued1
Convertible notes, maturity date
Debt Instrument Maturity Date
Extended debt instrument date
Debt Instrument Maturity Date Extended
Conversion rate
Debt Conversion Converted Instrument Rate
Conversion price
Debt Instrument Convertible Conversion Price1
Percentage of conversion price per share of common stock
Percentage Of Conversion Price Per Share Of Common Stock
Estimated value of put option liability
Debt instrument converted to common stock
Percentage of conversion price per share of convertible preferred stock.
Percentage of conversion price per share of preferred stock
Percentage Of Conversion Price Per Share Of Convertible Preferred Stock
Increase to put option liability.
Increase to put option liability
Increase To Put Option Liability
Maturities Of Long Term Debt [Abstract]
2021
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
2022
Long Term Debt Maturities Repayments Of Principal In Year Two
2023
Long Term Debt Maturities Repayments Of Principal In Year Three
2024
Long Term Debt Maturities Repayments Of Principal In Year Four
2025
Long Term Debt Maturities Repayments Of Principal In Year Five
Thereafter
Long Term Debt Maturities Repayments Of Principal After Year Five
Long-term debt
Long Term Debt
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Series A-1 preferred stock.
Series A-1 Preferred Stock
Series A1 Preferred Stock [Member]
Series A-2 preferred stock.
Series A2 Preferred Stock
Series A2 Preferred Stock [Member]
Series A-3 preferred stock.
Series A3 Preferred Stock
Series A3 Preferred Stock [Member]
Series B Preferred Stock
Series B Preferred Stock [Member]
Series C Preferred Stock
Series C Preferred Stock [Member]
Series D Preferred Stock
Series D Preferred Stock [Member]
Series E Preferred Stock
Series E Preferred Stock [Member]
Series B-1 Convertible Preferred Stock.
Series B1 Convertible Preferred Stock
Series B1 Convertible Preferred Stock [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Number of preferred stock converted into common stock.
Number of preferred stock converted into common stock
Number Of Preferred Stock Converted Into Common Stock
Class Of Warrant Or Right [Table]
Class Of Warrant Or Right [Table]
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Series E convertible preferred stock warrants.
Series E Convertible Preferred Stock Warrants
Series E Convertible Preferred Stock Warrants [Member]
Series G convertible preferred stock warrants.
Series G Convertible Preferred Stock Warrants
Series G Convertible Preferred Stock Warrants [Member]
Class Of Warrant Or Right [Line Items]
Class Of Warrant Or Right [Line Items]
Outstanding ‑ December 31, 2019, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
Granted, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
Forfeited/canceled, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
Exercised, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
Reclassification of warrant liability to additional paid-in capital, warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease
Outstanding ‑ December 31, 2020, warrants
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.
Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.
Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.
Weighted average exercise price, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
Weighted average exercise price, Granted
Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price
Weighted average exercise price, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Weighted average exercise price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price
Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital
Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price
Weighted average exercise price,Outstanding ‑ December, 31, 2020
Warrants expiry date
Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
Common stock, voting rights
Common Stock Voting Rights
Dividends
Dividends Common Stock
Direct offering expenses.
Common stock price per share
Sale Of Stock Price Per Share
Underwriting discounts and commissions
Expense Related To Distribution Or Servicing And Underwriting Fees
Direct offering expenses
Direct Offering Expenses
Preferred stock, issued
Disaggregation Of Revenue [Table]
Disaggregation Of Revenue [Table]
Diagnostic tests.
Diagnostic Tests
Diagnostic Tests [Member]
Services
Service [Member]
Disaggregation Of Revenue [Line Items]
Disaggregation Of Revenue [Line Items]
Advance deposits.
COVID-19 diagnostic test revenue.
COVID-19 Test Revenue
C O V I D19 Diagnostic Test Revenue [Member]
Lung diagnostic revenue.
Lung Diagnostic Revenue
Lung Diagnostic Revenue [Member]
Deferred revenue.
Deferred Revenue
Deferred Revenue [Member]
Advance deposits
Advance Deposits
Revenue recognized
Contract With Customer Liability Revenue Recognized
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Employee Stock Purchase Plan
Employee Stock [Member]
Plan Name
Plan Name [Axis]
Plan Name
Plan Name [Domain]
2020 equity incentive plan.
2020 Equity Incentive Plan
Two Thousand Twenty Equity Incentive Plan [Member]
2006 Plan.
2006 Plan
Two Thousand Six Plan [Member]
2016 Plan.
2016 Plan
Two Thousand And Sixteen Plan [Member]
Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.
2006 Plan, 2016 Plan and 2020 Equity Incentive Plan
Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Performance condition options.
Performance Condition Options
Performance Condition Options [Member]
Restricted Stock Units (RSUs)
Restricted Stock Units R S U [Member]
Bonus-to-options program.
Bonus-To-Options Program
Bonus To Options Program [Member]
Options and restricted stock units.
Options and Restricted Stock Units
Options And Restricted Stock Units [Member]
Service-condition RSUs.
Service Condition R S Us
Service Condition R S Us [Member]
Vesting
Vesting [Axis]
Vesting
Vesting [Domain]
Share-based Payment Arrangement, Tranche One
Share Based Compensation Award Tranche One [Member]
Share-based Payment Arrangement, Tranche Two
Share Based Compensation Award Tranche Two [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares reserved for issuance
Common Stock Capital Shares Reserved For Future Issuance
Percentage of number of shares of common stock issued and outstanding
Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
Description of voting power or value of stock for employee participation in offering period.
Description of offering period under plan.
Percentage of earnings used for purchase of common stock
Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
Percentage of fair market value of common stock for purchase under plan
Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
Description of voting power or value of stock for employee participation in offering period
Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period
Description of offering period under plan
Description Of Offering Period Under Plan
Number of common stock may be issued under incentive plan
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
Number of shares authorized
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
Additional stock awards granted
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
Option expiration period
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Number of equal annual installments for award vesting.
Vesting term
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
Number of equal annual installments for award vesting
Number Of Equal Annual Installments For Award Vesting
Number of performance-condition options granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Exercise price
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Options vested
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
Options forfeited
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Number of outstanding stock options granted
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Remaining life of outstanding performance condition options
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Vesting period
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
Percentage of fully diluted equity for bonus awarded.
Percentage of fully diluted equity for bonus awarded
Percentage Of Fully Diluted Equity For Bonus Awarded
Weighted average exercise price,vested
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Intrinsic value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Stock compensation expense
Allocated Share Based Compensation Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Research and Development
Research And Development Expense [Member]
Sales, Marketing, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total pre-tax share-based compensation expense
Unrecognized remaining stock based compensation balance
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Amortization period
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
Stock Options, Outstanding ‑ December 31, 2019
Stock Options, Granted
Stock Options, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
Stock Options, Exercised
Stock Options, Outstanding ‑ December 31, 2020
Stock Options, Exercisable ‑ December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Weighted Average Exercise Price, Outstanding ‑ December 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Forfeited/canceled
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Exercised
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding ‑ December 31, 2020
Weighted Average Exercise Price, Exercisable ‑ December 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.
Weighted Average Contractual Life (Years), Outstanding - December 31, 2019
Weighted Average Contractual Life (Years), Granted
Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1
Weighted Average Contractual Life (Years), Exercisable ‑ December 31, 2020
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
Aggregate Intrinsic Value, Outstanding - December 31, 2019
Aggregate Intrinsic Value, Outstanding - December 31, 2020
Aggregate Intrinsic Value, Outstanding - Exercisable ‑ December 31, 2020
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]
Risk‑free rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Expected term (in years)
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Expected dividend yield
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Expected volatility
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Vesting percentage
Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
Number of RSUs granted
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
RSUs outstanding
Weighted average grant date fair value
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
Earnings Per Share Basic And Diluted Other Disclosures [Abstract]
Numerator
Net Income Loss [Abstract]
Net loss attributable to common stockholders
Denominator
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Options to purchase common stock.
Options to Purchase Common Stock
Options To Purchase Common Stock [Member]
Warrants
Warrant [Member]
Restricted Stock Units
Convertible Debt
Convertible Debt Securities [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Provision for income taxes
Income Tax Expense Benefit
Effective income tax rate reconciliation permanent items.
Federal statutory income tax rate
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
State income taxes, net of federal benefit
Effective Income Tax Rate Reconciliation State And Local Income Taxes
Research and developments credits
Effective Income Tax Rate Reconciliation Tax Credits Research
Permanent items
Effective Income Tax Rate Reconciliation Permanent Items
Change in valuation allowance
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
Effective income tax rate
Effective Income Tax Rate Continuing Operations
Components Of Deferred Tax Assets [Abstract]
Deferred Tax Assets:
Deferred Tax Assets Net [Abstract]
Net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards
Research and development tax credits
Deferred Tax Assets Tax Credit Carryforwards Research
Property and equipment
Deferred Tax Assets Property Plant And Equipment
Stock-based compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Accruals and reserves
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
Total
Deferred Tax Assets Gross
Valuation allowance
Deferred Tax Assets Valuation Allowance
Total deferred tax assets after valuation allowance
Deferred Tax Assets Net
Deferred Tax Liabilities:
Deferred Tax Liabilities [Abstract]
Intangible assets
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
Total deferred tax liabilities
Deferred Income Tax Liabilities
Net deferred tax assets and liabilities
Deferred Tax Assets Liabilities Net
Deferred tax assets research and experimentation tax carryforwards subject to expiration.
Net operating loss carryforwards
Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
Research and experimentation tax carryforwards
Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration
Description of tax credit carryforward expiration
Tax Credit Carryforward Description
Percentage of valuation allowance equal to net deferred tax assets.
Valuation allowance, deferred tax asset, explanation of change
Valuation Allowance Deferred Tax Asset Explanation Of Change
Percentage of valuation allowance equal to net deferred tax assets
Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets
Increase in valuation allowance
Valuation Allowance Deferred Tax Asset Change In Amount
Accrued interest related to uncertain tax positions
Unrecognized Tax Benefits Interest On Income Taxes Accrued
Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward
Balance at January 1
Unrecognized Tax Benefits
Additions for tax positions related to the current year
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Additions for tax positions related to prior years
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
Reductions for tax positions related to prior years
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
Reductions related to settlements
Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
Reductions related to a lapse of statute
Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
Balance at December 31
Income tax examination details
Income Tax Examination Description
Loss Contingencies [Table]
Loss Contingencies [Table]
Bdx004.
BDX004
B D X004 [Member]
Industry Sector
Equity Securities By Industry [Axis]
Industry Sector
Equity Securities Industry [Member]
Ficlatuzumab.
Ficlatuzumab
Ficlatuzumab [Member]
Nsclc poc trial.
NSCLC POC Trial
N S C L C P O C Trial [Member]
Poc clinical trials.
POC Clinical Trials
P O C Clinical Trials [Member]
Bio-rad license.
Bio-Rad License
Bio Rad License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative
Type Of Arrangement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Arrangements And Nonarrangement Transactions [Member]
Revenue share agreement.
Revenue Share Agreement
Revenue Share Agreement [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Rent expense
Operating Leases Rent Expense Net
Leases [Abstract]
2021
Operating Leases Future Minimum Payments Due Current
2022
Operating Leases Future Minimum Payments Due In Two Years
2023
Operating Leases Future Minimum Payments Due In Three Years
2024
Operating Leases Future Minimum Payments Due In Four Years
2025
Operating Leases Future Minimum Payments Due In Five Years
Thereafter
Operating Leases Future Minimum Payments Due Thereafter
Total
Operating Leases Future Minimum Payments Due
Percentage of development and regulatory costs.
Responsible percentage of development and regulatory costs
Percentage Of Development And Regulatory Costs
Remaining estimated obligation.
Percentage of royalty payments on net sales.
Percentage of license income generated from licensing.
Remaining estimated obligation
Remaining Estimated Obligation
Percentage of royalty payments on net sales
Percentage Of Royalty Payments On Net Sales
Percentage of license income generated from licensing
Percentage Of License Income Generated From Licensing
Percentage of royalty payments on net revenue.
License agreement expiry date.
Percentage of royalty payments on net revenue
Percentage Of Royalty Payments On Net Revenue
License expiry date
License Agreement Expiry Date
Royalty expense
Royalty Expense
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.
Minimum annual volume percentage thereafter.
Period of escalations of sales.
Revenue share expenses.
Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests
Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests
Minimum annual volume percentage thereafter
Minimum Annual Volume Percentage Thereafter
Period of escalations of sales
Period Of Escalations Of Sales
Revenue share expenses
Revenue Share Expenses
Royalty expense
Payments For Royalties
Defined contribution plan, employer discretionary contributions amount
Defined Contribution Plan Employer Discretionary Contribution Amount
Defined Contribution Plan, Plan Name [Extensible List]
Defined Contribution Plan Plan Name Extensible List